

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Renji Medical Group Ltd

中國仁濟醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

CHANGE OF DIRECTORS

The Company announces that with effect from 4 September 2014:

- (i) Mr. Tang has tendered his resignation as an executive Director as well as the chairman of the Board and a member of the Corporate Governance Committee;
- (ii) Mr. Chan, an executive Director, has been elected as the Chairman of the Board;
- (iii) Dr. Hui has been appointed as an executive Director and a member of the Corporate Governance Committee; and
- (iv) Mr. Cheung has been appointed as an executive Director and a member of the Corporate Governance Committee.

CHANGE OF DIRECTORS

Resignation of Director

The board (the “Board”) of directors (the “Directors”) of China Renji Medical Group Limited (the “Company”) announces that Mr. Tang Chi Chiu (“Mr. Tang”) has tendered his resignation as an executive Director, the chairman of the Board and a member of the Corporate Governance Committee (the “Corporate Governance Committee”) of the Company with effect from 4 September 2014 for retirement. Mr. Tang has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation which need to be brought to the attention of the shareholders of the Company. Mr. Tang has also confirmed that he has no claims against the Company whether by way of compensation, severance payments, expenses or otherwise.

Appointment of Directors

The Board has also resolved to, with effect from 4 September 2014, (i) elect Mr. Chan Ka Chung (“Mr. Chan”), an executive Director, as the chairman of the Board; (ii) appoint Dr. Hui Ka Chun (“Dr. Hui”) as an executive Director and a member of the Corporate Governance Committee; and (iii) appoint Mr. Cheung Wei Kwan (“Mr. Cheung”) as an executive Director and a member of the Corporate Governance Committee.

Dr. Hui, aged 51, is a highly experienced executive with over 20 years of working experience in the areas of environmental services industry, manufacturing industry and innovative/hi-tech, clean energy industry in Hong Kong and the People’s Republic of China, including 13 years at senior executive management level in a number of renowned multinational companies (such as Swire Group and ABB Group). Dr. Hui holds a master’s degree in business administration and a doctorate’s degree in electrical engineering from the University of London, United Kingdom.

Mr. Cheung, aged 51, has over 20 years of management experience in distribution and manufacturing of a variety of products including chemical, food and medical products and has maintained an extensive network in Asia, particularly Japan and the People’s Republic of China. Mr. Cheung holds a master’s degree in business administration and a bachelor’s degree in business management from Asia University, Japan.

Save as disclosed above and as far as the Board is aware, Dr. Hui and Mr. Cheung have not held any directorship in other listed companies in Hong Kong in the last three years and does not have any relationship with any directors, senior management or substantial shareholders of the Company. As at the date of this announcement, Dr. Hui and Mr. Cheung are not interested in or deemed to be interested in any shares, underlying shares or debentures (as defined under Part XV of the Securities and Future Ordinance, Chapter 571 of the Laws of Hong Kong) of the Company. There are currently no service contracts entered into between the Company and Dr. Hui and Mr. Cheung, respectively. They will hold office until the next annual general meeting of the Company and thereafter and shall be subject to retirement by rotation and re-election once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company. The remuneration of Dr. Hui and Mr. Cheung will be determined with reference to their duties and responsibilities to be decided at a later date by the Board.

Save as disclosed above and as far as the Board is aware, there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited nor are there any other matters that is in relation to the appointment of Dr. Hui and Mr. Cheung that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Tang for his valuable contribution to the Company during his term of office with the Company and warmly welcome to Dr. Hui and Mr. Cheung joining the Board.

By Order of the Board of
China Renji Medical Group Limited
Chan Ka Chung
Chairman

Hong Kong, 4 September 2014

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Chan Ka Chung, Mr. Cheung Wai Kwan, Dr. Hui Ka Chun, and Mr. Wang Jianguo; and three independent non-executive Directors, namely, Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen and Ms. Wu Yan.